江苏吉贝尔药业股份有限公司 自愿披露关于收到化学原料药上市申请批准通知书的公告

Group 1 - The company has received approval from the National Medical Products Administration for the marketing application of Gatifloxacin, a chemical raw material drug [1][2] - Gatifloxacin is a broad-spectrum antibacterial agent effective against various bacteria, including Gram-positive and Gram-negative bacteria, and is the main raw material for the company's Gatifloxacin eye drops [2] - The approval is valid until October 21, 2030, and the company is required to continue accumulating research data on nitrosamine impurities and improve control strategies as necessary [2] Group 2 - The approved Gatifloxacin raw material is primarily intended to meet the production needs of the company's Gatifloxacin eye drops, and it is not expected to have a significant impact on the company's recent operations [3]